Similarly, research into LIPO-C components is likely to deepen, perhaps leading to novel blends or targeted delivery methods that further enhance their efficacy in supporting liver and metabolic health
Framing the conversation around your health and well-being can help your doctor see the bigger picture
4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)
Both groups were adjusted for baseline differences using propensity score weighting (eTable 1 in Supplement 1), so differences at follow-up could be attributed to the treatment